CellRep

Alfonso  Amat; Federico Perdomo-Celis; Manuel  Franco Cortés; Julian  Ganzabal; Luca  Gattinoni

CellRep

Alfonso Amat (Titular), Federico Perdomo-Celis (Titular), Manuel Franco Cortés (Inventor), Julian Ganzabal (Titular), Luca Gattinoni (Inventor)

Instituto de Genética Humana

Producción: Productos de Innovación › Spin-off

Resumen

CellRep pioneers dynamic cell reprogramming without gene editing, revolutionizing how cell therapies work. Our AI-powered platform discovers and validates compounds that enhance cellular function, addressing three critical limitations in current CAR-T therapies: poor efficacy in solid tumors, lengthy manufacturing time, and prohibitive costs. We're making personalized medicine truly scalable, starting with cancer treatments and soon expanding into longevity applications.

Idioma original	Inglés
Estado	Publicada - 01 ago. 2024

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Otros archivos y enlaces

https://cellrep.bio/

Citar esto

@misc{b85211b831dc4f5fae99f2cd846a03e6,

title = "CellRep",

abstract = "CellRep pioneers dynamic cell reprogramming without gene editing, revolutionizing how cell therapies work. Our AI-powered platform discovers and validates compounds that enhance cellular function, addressing three critical limitations in current CAR-T therapies: poor efficacy in solid tumors, lengthy manufacturing time, and prohibitive costs. We're making personalized medicine truly scalable, starting with cancer treatments and soon expanding into longevity applications.",

author = "Alfonso Amat and Federico Perdomo-Celis and \{Franco Cort{\'e}s\}, Manuel and Julian Ganzabal and Luca Gattinoni",

year = "2024",

month = aug,

day = "1",

language = "English",

type = "Patent",

}

TY - PAT

T1 - CellRep

AU - Franco Cortés, Manuel

AU - Gattinoni, Luca

A2 - Amat, Alfonso

A2 - Perdomo-Celis, Federico

A2 - Ganzabal, Julian

PY - 2024/8/1

Y1 - 2024/8/1

N2 - CellRep pioneers dynamic cell reprogramming without gene editing, revolutionizing how cell therapies work. Our AI-powered platform discovers and validates compounds that enhance cellular function, addressing three critical limitations in current CAR-T therapies: poor efficacy in solid tumors, lengthy manufacturing time, and prohibitive costs. We're making personalized medicine truly scalable, starting with cancer treatments and soon expanding into longevity applications.

AB - CellRep pioneers dynamic cell reprogramming without gene editing, revolutionizing how cell therapies work. Our AI-powered platform discovers and validates compounds that enhance cellular function, addressing three critical limitations in current CAR-T therapies: poor efficacy in solid tumors, lengthy manufacturing time, and prohibitive costs. We're making personalized medicine truly scalable, starting with cancer treatments and soon expanding into longevity applications.

UR - https://cellrep.bio/

M3 - Spin-off

ER -

CellRep

Resumen

ODS de las Naciones Unidas

Otros archivos y enlaces

Huella

Citar esto